Efficacy and Safety Study of Electroacupuncture for Simple Female Stress Urinary incontinence-a Multicenter Trial

Sponsor
Guang'anmen Hospital of China Academy of Chinese Medical Sciences (Other)
Overall Status
Completed
CT.gov ID
NCT01784172
Collaborator
Ministry of Science and Technology of the People´s Republic of China (Other)
504
1
2
21
24

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the efficacy and safety of electroacupuncture (EA) for simple female stress urinary incontinence.

Condition or Disease Intervention/Treatment Phase
  • Device: electroacupuncture group
  • Device: sham electroacupuncture group
Phase 2

Detailed Description

Stress urinary incontinence (SUI) is a common disease of female. The inconvenience caused by SUI affects the patients' quality of life and health seriously. To date, there has not specific therapy on SUI. Former research showed acupuncture may work for SUI. This multi-center randomized controlled clinical trial of acupuncture for simple female stress urinary incontinence is designed to confirm the efficacy and safety of EA. This project is conducted by Chinese researchers, supported by the Chinese Government. The research result is expected to provide high quality evidence of EA for simple female stress urinary incontinence.

Study Design

Study Type:
Interventional
Actual Enrollment :
504 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
The Efficacy and Safety Study of Electro-acupuncture for Simple Female Stress Urinary Incontinence- a Multicenter, Randomized Controlled Trial
Study Start Date :
Mar 1, 2013
Actual Primary Completion Date :
Dec 1, 2014
Actual Study Completion Date :
Dec 1, 2014

Arms and Interventions

Arm Intervention/Treatment
Experimental: electroacupuncture group

Bilateral BL33 are given acupuncture of 50~60mm with 30~45°angle to inward and downward. Bilateral B L35 are given acupuncture of 50~60mm to outward and upward. The electric stimulator is applied to bilateral BL33 and BL35. Every session lasts for 30 min per day. The participants are treated continuously for 6 weeks for 3 sessions a week, 18 sessions for each patient in all.

Device: electroacupuncture group
Procedure: electro-acupuncture;Points: Bilateral Zhongliao (BL33) Huiyang(BL35).Specially-made pad is stick on pierced acupoints. Bilateral BL33 are given acupuncture of 50~60mm with 30~45°angle to inward and downward by 75mm filiform needle. Bilateral BL35 are given acupuncture of 50~60mm to outward and upward by 75mm filiform needle. Twirl, lift and thrust for 3 times, until local sour and heavy feeling coming.The electric stimulator is applied to bilateral BL33 and BL35, with continuous wave,50 Hz and electric current 1- 5mA.Every session lasts for 30 min per day.The participants are treated continuously for 6 weeks for 3 sessions a week, 18 sessions for each patient in all. The treatment is designed based on recent literature research in 10 years, former result and expert consensus.
Other Names:
  • SDA-V electroacupuncture apparatus(Huatuo,made in China)
  • Experimental: sham electroacupuncture group

    Bilateral sham BL33 and sham BL35 are given sham electroacupuncture with no current output. Every session lasts for 30 min per day. The participants are treated continuously for 6 weeks for 3 sessions a week, 18 sessions for each patient in all.

    Device: sham electroacupuncture group
    Procedure: sham electroacupuncture;Points: Bilateral sham Zhongliao (BL33) sham Huiyang(BL35).Specially-made pad is stick on pierced acupoints. Both sham BL33 and BL35 are given non-penetrating needling with blunt needle. Twirl, lift and thrust for 3 times. The sham electric stimulator is applied to bilateral sham BL33 and sham BL35. The mental wire has been cut off with a same outlook as the treatment group. The electric stimulator is looked normal but with no current output. Length of Treatment and the treatment sessions are the same as treatment group.
    Other Names:
  • Sham SDZ-V electroacupuncture apparatus(Huatuo,China)
  • Outcome Measures

    Primary Outcome Measures

    1. value difference of 1h pad test, compared with the baseline [the 6 weeks]

      quantity of fluid loss will be measured by 1h pad test, comparing the value of 6 weeks with the baseline(0 week), the primary outcome is the value difference.

    Secondary Outcome Measures

    1. average frequency difference of urinary incontinence in 72h [the 6 weeks, the15-18 weeks, 27-30 weeks]

      1. The average frequency difference of urinary incontinence in 72h of the 6 weeks is the average frequency difference of urinary incontinence in 72h of 2nd, 4th, 6th weeks based on the '72h voiding diary'; 2. The average frequency difference of urinary incontinence in 72h of the15-18 weeks is the average frequency difference of urinary incontinence in 72h of 15-18 weeks based on the '72h voiding diary'; 3. The average frequency difference of urinary incontinence in 72h of the 27-30 weeks is the average frequency difference of urinary incontinence in 72h of 27-30 weeks based on the '72h voiding diary'.

    2. ICIQ-SF [the 6, 18, 30 week]

      International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF) is a brief instrument used to assess the impact of UI in patients'lives

    3. Patient subjective effectiveness evaluation [the 6, 18, 30 week]

      3 point scoring: no help=0; Small help=1; Medium help=2; Great help=3

    4. Weekly usage of pad [the 6 weeks, 7-18weeks, 19-30 weeks]

      The value of 6 weeks is the average weekly usage of pads during 1-6 week; The value of 7-18weeks is the average weekly usage of pads during 7-18 weeks; The value of 19-30 weeks is the average weekly usage of pads during 19-30 weeks.

    5. Usage of specialty therapy for Simple female stress urinary incontinence [the 6 weeks, 7-18weeks, 19-30 weeks]

      Compare the difference of uase of specialty therapy for Simple female stress urinary incontinence between the 2 groups during the 1-6 weeks, 7-18 weeks and 19-30 weeks.

    6. subgroup analysis: Relevency between 1h pad test, frequency of urinary incontinence in 72h and extent of urinary incontinence [the 6, 18, 30 week]

      the 6th week: analyse the relevancy between 1h pad test and extent of urinary incontinence; the 18th and 30th weeks: analyse the relevancy between frequency of urinary incontinence in 72h and extent of urinary incontinence.

    7. Incidence of adverse events [the 1-6 weeks]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    40 Years to 75 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Meet the diagnosis of Simple female stress urinary incontinence

    • 40-75 years old

    • Volunteered to join this research and signed the informed consent

    Exclusion Criteria:
    • urge urinary incontinence, mixed urinary incontinence, overflow urinary incontinence, etc

    • After operation for urinary incontinence or pelvic floor operation

    • Edeoptosis≥Degree 2

    • Symptomatic urinary tract infection

    • RUV>30ml

    • Qmax<20ml/s

    • Constrained movement of walking, stairs climbing, running

    • Patients with continuous treatment for stress urinary incontinence or medicine for bladder function

    • With serious cardiovascular, cerebral, liver, kidney, or psychiatric disease, diabetes, MSA, Injury of cauda equine, myeleterosis.

    • During pregnancy or lactation period

    • With cardiac pacemaker, Metal allergy or severe needle phobia

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 China Academy of Chinese Medical Sciences Beijing Beijing China 100700

    Sponsors and Collaborators

    • Guang'anmen Hospital of China Academy of Chinese Medical Sciences
    • Ministry of Science and Technology of the People´s Republic of China

    Investigators

    • Principal Investigator: Baoyan Liu, Master, China Academy of Chinese Medical Sciences

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Liu Baoyan, Vice President of China Academy of Chinese Medical Sciences, Guang'anmen Hospital of China Academy of Chinese Medical Sciences
    ClinicalTrials.gov Identifier:
    NCT01784172
    Other Study ID Numbers:
    • 2012BAI24B01-2
    First Posted:
    Feb 5, 2013
    Last Update Posted:
    Dec 23, 2014
    Last Verified:
    Dec 1, 2014
    Keywords provided by Liu Baoyan, Vice President of China Academy of Chinese Medical Sciences, Guang'anmen Hospital of China Academy of Chinese Medical Sciences
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Dec 23, 2014